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Hepaticiron depositionAbstract Introduction: The purpose of this study is to detect the role of breath-hold multiecho
T2*-weighted MRI, in quantiﬁcation of hepatic iron deposition in patients with sickle cell disease.
Methods: Thirty-seven patients underwent 1.5-T MRI of the liver that included a multiecho
T2*-weighted sequence. Hepatic T2* iron grading was done for each patient by placing regions
of interest in the hepatic parenchyma. Hepatic T2* values were correlated with histopathological
iron grade. Liver biopsy was done for all patients. Written consent was obtained from all patients
prior to MRI studies.
Results: Thirty-two patients (86.5 %) had evidence of hepatic iron deposition on histopathological
examination, including eight (25%) with grade 3, eleven (34%) with grade 2 and thirteen patients
(41%) with grade 1.
Patients with negative iron deposition histologically, had T2* values ranging from 28–32 ms. For
the patients with positive hepatic iron deposition, hepatic T2* decreased with increasing iron grade.
Statistical analysis showed that for differentiation of hepatic iron deposition grade 3 from grades
1 and 2, hepatic T2* less than 13 ms had a sensitivity and speciﬁcity of 100 % and 98%, respectively.
Conclusion: Breath-hold multiecho T2*-weighted MRI sequence offers an accurate estimation of
hepatic iron deposition.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine.Open access under CC BY-NC-ND license.1. Introduction
In patients with primary haemochromatosis, iron overload has
been associated with the development of hepatic ﬁbrosis,
cirrhosis, and hepatocellular carcinoma (1,2). Assessment of
body iron stores using ferritin level in blood has poor speciﬁc-
ity (3). Histopathological analysis of core hepatic biopsy spec-
imens with biochemical and histopathological techniques is
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tiﬁcation of iron in the liver (4). This type of analysis, however,
is limited by cost, risk of morbidity, and sampling error, hav-
ing a large coefﬁcient of variation due to nonuniform iron
deposition (5,6).
Iron hepatic deposition cannot be detected by ultrasound.
Hyper density on CT scan is nonspeciﬁc and could be masked
by associated steatosis (7,8). MRI has been investigated for the
detection and quantiﬁcation of hepatic iron deposition. Detec-
tion of iron with MRI is based on local ﬁeld inhomogeneity
generated mostly by the paramagnetic effect of hemosiderin
particles. Spin-echo and gradient-echo sequences have been
investigated over the last two decades with good results
(9,10). However, some of the proposed methods need complex
mathematic modeling, calibration, and post processing, which
limit their use in clinical practice. Furthermore, with most of
these methods, a single slice through the liver is sampled, giv-
ing no beneﬁt over the sampling limitations of liver biopsy.
Because of the limitations of current techniques, there is a need
for a simple, quick, and accurate method of detection and
quantiﬁcation of iron in the liver. An easy to perform multi-
echo T2*-weighted sequence for myocardial iron quantiﬁcation
has been investigated with good results (11,12). The objective
of our study was to conduct, with histopathological examina-
tion as the reference standard, an evaluation of the use of a
breath-hold multiecho T2*-weighted MRI sequence for detec-
tion and quantiﬁcation of hepatic iron deposition in patients
with sickle cell disease.2. Materials and methods
2.1. Patient population
The study was conducted during the period from March, 2012,
until March 2013. Thirty-seven patients with sickle cell disease
were included. The mean age of patients was 26 years; range,
15–30 years. Thirty-two of the patients were males and ﬁve
were females.
Hepatic MRI, including a T2*-weighted sequence, was per-
formed for all patients. Written consent was obtained prior to
MRI examinations. All patients underwent liver biopsies
within 90 days of imaging.
2.2. MRI examination
All patients underwent MRI with a 1.5-T machine (Optima
MR 450 W, GE Healthcare, South Carolina, USA) using a
body coil. For T2*-weighted imaging, an axial gradient-
recalled, breath-hold, multiecho T2* sequence was performed.
The parameters were as follows: TR/TE, 35.3–39.9/4.7, 9.5,
14.3, 19.1, 24.0, and 28.7 ms; ﬂip angle 25; slice thickness,
8 mm; interslice gap, 5 mm; matrix size, 96 · 96 and
128 · 128; ﬁeld of view, 42 mm; number of signals acquired,
1; bandwidth, 125 Hz/pixel; 3–5 slices acquired through mid
liver; acquisition time, 16–20 s.
The patients underwent a routine liver protocol that
included the following breath-hold sequences: coronal T2-
weighted FSE (fast spin echo), transverse FSE T2-weighted
with fat saturation, transverse T1-weighted FSE, and trans-
verse 3D T1-weighted fat saturated FES.2.3. Image evaluation
Two consecutive T2* slices at mid liver (mid portal vein level)
were analyzed. Axial slices closer to the liver dome were
excluded because of the risk of susceptibility artifact from air
in the adjacent lung. Two regions of interest (ROIs) were
placed in the liver parenchyma to measure the signal intensity
in the right anterior and right posterior hepatic segments of
each slice. ROIs measured approximately 2–3 cm2. An average
of the values of the ROIs was calculated in each patient.
2.4. Histopathological evaluation
Tissue specimens were obtained within 90 days of MRI via
percutaneous core liver biopsy. The histopathologists graded
the degree of iron deposition with a semi quantitative method
based on the results of Perls Prussian blue staining, as follows:
grade 0, iron granules absent or barely discernible in a high-
power ﬁeld (·400); grade 1, granules easily conﬁrmed at
·400 or barely discernible at ·250; grade 2, granules resolved
at ·100; grade 3, granules resolved at ·25; and grade 4, masses
visible at low power (·10) or with the naked eye.
2.5. Statistical analysis
A nonparametric Mann–Whitney test was used to make a
comparison between T2* and iron grade: grades 1 and 2 versus
grade 3, grade 1 versus grade 2, and grade 2 versus grade
3. Receiver operating characteristics analysis was performed
to assess the utility of T2* for discriminating patients with
different iron grades.
3. Results
Thirty-two patients (86.5%) had evidence of hepatic iron
deposition on histopathological examination, including eight
(25%) with grade 3, eleven (34%) with grade 2 and thirteen
patients (41%) with grade 1 (Fig. 1 and 2).
Patients with negative iron deposition histologically, had
T2* values ranging from 28–32 ms. For the patients with posi-
tive hepatic iron deposition, hepatic T2* decreased with
increasing iron grade. Patients with liver iron deposition grade
3 had signiﬁcantly lower T2* values than patients with grade
1 and 2 iron deposition. T2* values for grades 1 and 2 iron
deposition ranged from 20–23 to 17–19 ms, respectively, while
those for grade 3 were all less than 13 ms. There was no signif-
icant difference in T2* values between patients with grade
1 and those with grade 2 iron deposition.
Statistical analysis showed that for differentiation of hepa-
tic iron deposition grade 3 from grades 1 and 2, hepatic T2*
less than 13 ms had a sensitivity and speciﬁcity of 100% and
98%, respectively (Table 1).
4. Discussion
Although iron is an essential mineral, in excessive amounts, it
can be toxic to the human body. Its deleterious effects are
thought to be due to increased oxidative stress on the body
(13,14). Iron within hepatocytes and increased total body iron
in haemochromatosis are associated with an increased risk of
Fig. 1 Breath-hold axial gradient-recalled echo T2* MR images in a 26-year-old male with sickle cell disease and grade 2 iron deposition.
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identify the presence of excessive intrahepatic iron. The refer-
ence standard for hepatic iron quantiﬁcation is core liver
biopsy (15). However, this technique has its own limitations,
like being relatively invasive and difﬁcult to repeat. Serum
indicators of iron do not necessarily reﬂect tissue iron levels
(16,17).
MRI has emerged as a readily available noninvasive means
of quantifying hepatic iron (18,19). Various MRI sequences
have been investigated for iron detection and quantiﬁcation.
Signal intensity ratio and relaxometric methods have been
described and validated with spin-echo and gradient-echo tech-
niques. Most of these sequences have long acquisition times or
require labor-intensive post processing and calibration curves
(9,10). Breath-hold multiecho T2*-weighted sequences have
been evaluated for cardiac and liver iron quantiﬁcation
(11,12,19,20).Wood et al. (21) studied a breath-hold multiecho T2*-
weighted sequence for hepatic iron quantiﬁcation. They used
short TEs (0.8–4.8 ms) for imaging of pediatric patients with
blood dyscrasia. In that study, liver T2* correlated highly with
dry iron weight at biopsy (coefﬁcient of correlation, 0.97). We
followed his league in our study, performing T2* MRI for
patients with sickle cell disease, but, in adolescents and young
adults.
In contrast to the sequence used in the study by Wood et al.
(21), multiecho T2*-weighted sequence including longer TEs,
the longest being equal to or slightly larger than the T2* value
of normal liver (greater than 24 ms at 1.5 T), was reported in
previous studies (11,19,20). We used the same T2*-weighted
sequence in our study.
Iron is stored in the liver as iron (III) oxyhydroxide parti-
cles in the form of ferritin and hemosiderin. Hemosiderin is
a degradation product of ferritin particles. Although it has a
Fig. 2 Breath-hold axial gradient-recalled echo T2* MR images in a 29-year-old male with sickle cell disease and grade 3 iron deposition.
Table 1 Statistical analysis for sensitivity and speciﬁcity of T2* for differentiation of different grades of hepatic siderosis.
Iron Grade Cutoﬀ T2* value (ms) Area under the curve Sensitivity (%) Speciﬁcity (%)
P1 <24 0.964 (0.864–0.99) 92.1 (71.0–99.1) 100 (83.9–100)
P2 <20 0.948 (0.820–0.99) 100 (64.0–100) 82 (64.9–93.7)
P3 <13 0.984 (0.882–0.99) 100 (51.9–100) 98.0 (86.0–100)
654 F.M. Awad, S.A. Alshazlysmaller core, hemosiderin is insoluble and more likely to aggre-
gate than ferritin (22,23). Studies have shown that hemosiderin
has a strong T2 relaxation effect (24). Hence, in our study,
decreased T2* readings in the liver increased with increasing
degree of hepatic siderosis.
The breath-hold T2*-weighted sequence is easy to perform,
as are image post processing and interpretation. We believe
this sequence can serve an important function in stratifying
patients on the basis of iron overload. T2*-weighted MRI
may be useful for follow-up of patients with hepatic siderosis
and obviate repeated biopsies, particularly in the care of
patients treated with iron-chelating therapy (25). These ﬁnd-
ings go with the data in our study which showed high sensitiv-
ity and speciﬁcity of T2* in differentiating patients with hepatic
siderosis from those without, and patients with Grade 1 and 2
siderosis from those with grade 3.
According to Lim et al. (26), T2* was able to differentiate
the different degrees of hepatic siderosis even grade 1 and 2.
In our study, there was no signiﬁcant difference between
results of T2* in patients with grade 1 and 2 siderosis. The dif-
ference could be due to the small number of patient population
in our study.
We concluded that multiecho breath-hold T2*-weighted
gradient-recalled echo sequence is useful for rapid and nonin-vasive assessment of hepatic iron overload and may obviate
core liver biopsy in the diagnosis of hepatic siderosis in
patients with sickle cell disease.Conﬂict of interest
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